: Gained 387% due to positive developments in its painkiller and immuno-oncology portfolio.
: One of the year's biggest winners, surging 438% . The biotech firm saw its valuation jump from roughly $200 million to over $1.4 billion following a key collaboration with a major pharmaceutical player.
The top of the leaderboard was dominated by small-to-mid-cap biotechnology firms that saw astronomical returns following clinical trial successes or major partnerships. top stocks to buy 2017
: The top-performing stock in the S&P 500 for 2017, rising 121% . Its turnaround was fueled by a restructuring plan and a shift in investor sentiment toward utility companies.
For more conservative investors, the major indices also provided significant "win" stories through well-known household names. : Gained 387% due to positive developments in
: Returned 373% after receiving FDA approval for its hepatitis B vaccine.
: The maker of Invisalign rose 131% as clear aligners began capturing a massive share of the dental market. Blue-Chip and Large-Cap Winners The top of the leaderboard was dominated by
The year 2017 was a landmark year for equity markets, characterized by a massive surge in and semiconductors . While the tech giants of the "FANG" era (Facebook, Amazon, Netflix, Google) continued to post impressive gains, the true "breakout" stories came from specialized medical research and the chips powering the digital revolution. The Best Performing Stocks of 2017